Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Öz Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients' records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment was one (1-4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32 and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due to AEs. Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.

Kaynak Göster

Bibtex @ { tbtkmedical576723, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2018}, volume = {48}, pages = {777 - 785}, doi = {}, title = {Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience}, key = {cite}, author = {Soyer, Nur and Patır, Püsem and Uysal, Ayşe and Duran, Mustafa and Ünal, Hatice Demet Kiper and Onmuş, İsabel Raika Durusoy and Tombuloğlu, Murat and Şahin, Fahri and Töbü, Mahmut and Vural, Filiz and Saydam, Güray} }
APA Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . (2018). Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience . Turkish Journal of Medical Sciences , 48 (4) , 777-785 . Retrieved from https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45702/576723
MLA Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience" . Turkish Journal of Medical Sciences 48 (2018 ): 777-785 <https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45702/576723>
Chicago Soyer, N , Patır, P , Uysal, A , Duran, M , Ünal, H , Onmuş, İ , Tombuloğlu, M , Şahin, F , Töbü, M , Vural, F , Saydam, G . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience". Turkish Journal of Medical Sciences 48 (2018 ): 777-785
RIS TY - JOUR T1 - Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience AU - Nur Soyer , Püsem Patır , Ayşe Uysal , Mustafa Duran , Hatice Demet Kiper Ünal , İsabel Raika Durusoy Onmuş , Murat Tombuloğlu , Fahri Şahin , Mahmut Töbü , Filiz Vural , Güray Saydam Y1 - 2018 PY - 2018 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 777 EP - 785 VL - 48 IS - 4 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2021 ER -
EndNote %0 Turkish Journal of Medical Sciences Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience %A Nur Soyer , Püsem Patır , Ayşe Uysal , Mustafa Duran , Hatice Demet Kiper Ünal , İsabel Raika Durusoy Onmuş , Murat Tombuloğlu , Fahri Şahin , Mahmut Töbü , Filiz Vural , Güray Saydam %T Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience %D 2018 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 48 %N 4 %R %U
ISNAD Soyer, Nur , Patır, Püsem , Uysal, Ayşe , Duran, Mustafa , Ünal, Hatice Demet Kiper , Onmuş, İsabel Raika Durusoy , Tombuloğlu, Murat , Şahin, Fahri , Töbü, Mahmut , Vural, Filiz , Saydam, Güray . "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience". Turkish Journal of Medical Sciences 48 / 4 (Ağustos 2018): 777-785 .
AMA Soyer N , Patır P , Uysal A , Duran M , Ünal H , Onmuş İ , Tombuloğlu M , Şahin F , Töbü M , Vural F , Saydam G . Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. Turkish Journal of Medical Sciences. 2018; 48(4): 777-785.
Vancouver Soyer N , Patır P , Uysal A , Duran M , Ünal H , Onmuş İ , Tombuloğlu M , Şahin F , Töbü M , Vural F , Saydam G . Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience. Turkish Journal of Medical Sciences. 2018; 48(4): 777-785.
IEEE N. Soyer , P. Patır , A. Uysal , M. Duran , H. Ünal , İ. Onmuş , M. Tombuloğlu , F. Şahin , M. Töbü , F. Vural ve G. Saydam , "Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience", Turkish Journal of Medical Sciences, c. 48, sayı. 4, ss. 777-785, Ağu. 2018

8364 6495

Arşiv
Sayıdaki Diğer Makaleler

Octreotide ameliorates dermal fibrosis in bleomycin-induced scleroderma

SİBEL OYUCU ORHAN, AHMET TEKTEMUR, NEVZAT GÖZEL, İBRAHİM HANİFİ ÖZERCAN, Servet YOLBAŞ, AHMET YILDIRIM, EBRU ÖNALAN, Süleyman Serdar KOCA

Ginger (Zingiber officinale) prevents severe damage to the lungs due to hyperoxia and inflammation

ATİLLA ÇİFCİ, CÜNEYT TAYMAN, HALİL İBRAHİM YAKUT, Halit HALİL, ESRA ÇAKIR, Ufuk ÇAKIR, SALİH AYDEMİR

Peripheral arterial disease increases the risk of multidrug-resistant bacteria and amputation in diabetic foot infections

Pinar Aysert YILDIZ, Tuğba ÖZDİL, MURAT DİZBAY, Özlem Güzel TUNÇCAN, Kenan HIZEL

Effect of intraoperative infusion of sufentanil versus remifentanil on postoperative shivering in Korea: a prospective, double-blinded, randomized control study

Ki Tae JUNG, Keum Young SO, İn Gook JEE, Sang Hun KIM

Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)

Ayperi ÖZTÜRK, Oya KAYACAN

The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation

Seyed Ahmad HOSEİNİAN, Davood JAFARİ, Mehdi MAHMOODİ, Kamran ALİMOGHADDAM, Mohammadreza OSTADALİ, Azita Talebzadeh BONAKDAR, Arron Munggela FOMA, Mir Saeed YEKANİNEJAD, Ali Akbar AMİRZARGAR

Relationship of serum HLA-B alleles and TNF-? with rheumatic heart disease

Mustafa Azmi EYİOL, Çağri YAYLA, Serkan ÜNLÜ, Abdurrahman TUFAN, Mustafa CEMRİ, Mehmet Ridvan YALÇIN, Nuri Bülent BOYACI

Methodology of a new inflammatory arthritis registry: TReasure

Umut KALYONCU, Etem Koray TAŞCILAR, Ali İhsan ERTENLİ, Hüseyin Ediz DALKILIÇ, Cemal BES, ORHAN KÜÇÜKŞAHİN, Timuçin KAŞİFOĞLU, Nilüfer Alpay KANITEZ, Hakan EMMUNGİL, GEZMİŞ KİMYON, Nazife Şule Yaşar BİLGE, Servet AKAR, Mehmet Pamir ATAGÜNDÜZ, SÜLEYMAN SERDAR KOCA, Aşkin ATEŞ, VELİ YAZISIZ, Mustafa Ender TERZİOĞLU, Em

Detection of CCND1, C-MYC, and FGFR1 amplification using modified SYBR Green qPCR and FISH in breast cancer

Asaad AZARNEZHAD, Mina TABRIZI, Firozeh JAVAN, Parvin MEHDIPOUR

Takayasu arteritis: an update

Gökhan KESER, Kenan AKSU, Rafi Haner DİRESKENELİ